Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADPT Adaptive Biotechnologies	$10.39 -1.0%	$10.37	$3.85 ▼ $12.43	$1.58B	1.83	1.64 million shs	1.44 million shs
HRMY Harmony Biosciences	$35.20 -3.4%	$33.82	$26.47 ▼ $41.61	$2.02B	0.83	668,364 shs	701,636 shs
SIGA Siga Technologies	$6.61 -1.3%	$6.31	$4.95 ▼ $12.83	$472.22M	0.94	712,416 shs	271,602 shs
SPRY ARS Pharmaceuticals	$17.92 -2.3%	$15.52	$8.91 ▼ $18.90	$1.76B	0.9	1.53 million shs	1.34 million shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADPT Adaptive Biotechnologies	-3.05%	-13.08%	+3.55%	+43.25%	+141.38%
HRMY Harmony Biosciences	+3.46%	+6.12%	+12.20%	+28.00%	+10.13%
SIGA Siga Technologies	-1.18%	-2.90%	+6.35%	+11.85%	-25.64%
SPRY ARS Pharmaceuticals	+2.69%	+2.06%	+23.82%	+23.32%	+61.96%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADPT Adaptive Biotechnologies	2.7889 of 5 stars	1.4	1.0	4.2	2.7	2.5	0.6
HRMY Harmony Biosciences	4.8037 of 5 stars	4.5	1.0	0.0	3.4	3.3	4.4
SIGA Siga Technologies	2.0281 of 5 stars	0.0	3.0	0.0	1.5	0.8	3.1
SPRY ARS Pharmaceuticals	2.8987 of 5 stars	3.6	1.0	0.0	2.2	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADPT Adaptive Biotechnologies	2.86	Moderate Buy	$10.57	1.75% Upside
HRMY Harmony Biosciences	3.00	Buy	$51.33	45.83% Upside
SIGA Siga Technologies	0.00	N/A	N/A	N/A
SPRY ARS Pharmaceuticals	3.17	Buy	$31.00	72.99% Upside

Current Analyst Ratings Breakdown

Latest SIGA, HRMY, ADPT, and SPRY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	HRMY Harmony Biosciences	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $55.00
7/10/2025	HRMY Harmony Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold	$33.00
6/18/2025	ADPT Adaptive Biotechnologies	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
6/2/2025	HRMY Harmony Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$61.00
5/15/2025	HRMY Harmony Biosciences	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$44.00 ➝ $48.00
5/13/2025	HRMY Harmony Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/6/2025	ADPT Adaptive Biotechnologies	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$11.00 ➝ $13.00
5/6/2025	HRMY Harmony Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$49.00 ➝ $49.00
5/5/2025	ADPT Adaptive Biotechnologies	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$7.00 ➝ $9.00
5/2/2025	ADPT Adaptive Biotechnologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $10.00
4/28/2025	HRMY Harmony Biosciences	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$55.00 ➝ $48.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADPT Adaptive Biotechnologies	$178.96M	8.82	N/A	N/A	$1.37 per share	7.58
HRMY Harmony Biosciences	$714.73M	2.83	$2.95 per share	11.95	$11.56 per share	3.04
SIGA Siga Technologies	$138.72M	3.40	$0.82 per share	8.10	$3.02 per share	2.19
SPRY ARS Pharmaceuticals	$89.15M	19.74	$0.01 per share	2,110.22	$2.64 per share	6.79

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADPT Adaptive Biotechnologies	-$159.49M	-$0.96	N/A	N/A	N/A	-74.84%	-62.79%	-24.55%	8/5/2025 (Estimated)
HRMY Harmony Biosciences	$145.49M	$2.62	13.44	11.32	0.48	20.53%	24.32%	15.92%	8/5/2025 (Estimated)
SIGA Siga Technologies	$59.21M	$0.67	9.87	5.29	N/A	40.30%	25.21%	22.05%	7/30/2025 (Estimated)
SPRY ARS Pharmaceuticals	$8M	-$0.16	N/A	N/A	N/A	-16.11%	-6.94%	-5.60%	8/5/2025 (Estimated)

Latest SIGA, HRMY, ADPT, and SPRY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	ADPT Adaptive Biotechnologies	-$0.24	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	HRMY Harmony Biosciences	$0.78	N/A	N/A	N/A	$204.37 million	N/A
8/5/2025	Q2 2025	SPRY ARS Pharmaceuticals	-$0.42	N/A	N/A	N/A	$12.92 million	N/A
5/14/2025	Q1 2025	SPRY ARS Pharmaceuticals	-$0.35	-$0.35	N/A	-$0.35	$7.48 million	$7.97 million
5/8/2025	Q1 2025	SIGA Siga Technologies	N/A	-$0.01	N/A	-$0.01	N/A	$7.04 million
5/6/2025	Q1 2025	HRMY Harmony Biosciences	$0.59	$0.78	+$0.19	$0.78	$184.26 million	$184.73 million
5/1/2025	Q1 2025	ADPT Adaptive Biotechnologies	-$0.28	-$0.20	+$0.08	-$0.20	$42.13 million	$52.44 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADPT Adaptive Biotechnologies	N/A	N/A	N/A	N/A	N/A
HRMY Harmony Biosciences	N/A	N/A	N/A	N/A	N/A
SIGA Siga Technologies	N/A	N/A	N/A	N/A	N/A
SPRY ARS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADPT Adaptive Biotechnologies	N/A	2.92	2.82
HRMY Harmony Biosciences	0.22	3.67	3.63
SIGA Siga Technologies	N/A	8.40	6.28
SPRY ARS Pharmaceuticals	0.30	11.00	10.74

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADPT Adaptive Biotechnologies	99.17%
HRMY Harmony Biosciences	86.23%
SIGA Siga Technologies	55.40%
SPRY ARS Pharmaceuticals	68.16%

Insider Ownership

Company	Insider Ownership
ADPT Adaptive Biotechnologies	6.40%
HRMY Harmony Biosciences	23.60%
SIGA Siga Technologies	1.95%
SPRY ARS Pharmaceuticals	33.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADPT Adaptive Biotechnologies	790	151.92 million	142.19 million	Optionable
HRMY Harmony Biosciences	200	57.42 million	43.87 million	Optionable
SIGA Siga Technologies	40	71.44 million	70.05 million	Optionable
SPRY ARS Pharmaceuticals	90	98.21 million	65.31 million	Optionable

SIGA, HRMY, ADPT, and SPRY Headlines

Recent News About These Companies

EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

July 18 at 9:25 AM | globenewswire.com

What Makes ARS Pharmaceuticals, Inc. (SPRY) a Good Fit for 'Trend Investing'

July 15 at 8:04 PM | sharewise.comS

ARS Pharmaceuticals, Inc. (SPRY) is a Great Momentum Stock: Should You Buy?

July 15 at 1:01 PM | zacks.com

Wall Street Analysts See a 78.77% Upside in ARS Pharmaceuticals, Inc. (SPRY): Can the Stock Really Move This High?

July 15 at 10:56 AM | zacks.com

What Makes ARS Pharmaceuticals, Inc. (SPRY) a Good Fit for 'Trend Investing'

July 15 at 9:50 AM | zacks.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives $31.00 Consensus Price Target from Brokerages

July 14, 2025 | americanbankingnews.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Consensus Rating of "Buy" by Brokerages

July 11, 2025 | marketbeat.com

ARS Pharmaceuticals: High Risk High Reward Rollout Of No Needle Epinephrine

July 10, 2025 | seekingalpha.com

ARS Pharmaceuticals: 'Betting On The Come'

July 9, 2025 | seekingalpha.com

ARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Up 4.6% - Should You Buy?

July 7, 2025 | marketbeat.com

Allspring Global Investments Holdings LLC Raises Stock Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

July 6, 2025 | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells $254,850.00 in Stock

July 4, 2025 | insidertrades.com

Insider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells 15,000 Shares of Stock

July 3, 2025 | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Major Shareholder James E. Flynn Sells 740,149 Shares

July 2, 2025 | insidertrades.com

James E. Flynn Sells 740,149 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock

July 1, 2025 | marketbeat.com

Peregrine Capital Management LLC Boosts Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

July 1, 2025 | marketbeat.com

ARS Pharmaceuticals (NASDAQ:SPRY) Trading Down 5% - Here's What Happened

June 30, 2025 | marketbeat.com

Lisanti Capital Growth LLC Buys New Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

June 29, 2025 | marketbeat.com

55,714 Shares in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Purchased by Matisse Capital

June 28, 2025 | marketbeat.com

ARS Pharmaceuticals (NASDAQ:SPRY) Upgraded at Wall Street Zen

June 28, 2025 | marketbeat.com

ARS Pharmaceuticals (NASDAQ:SPRY) Sets New 12-Month High - Still a Buy?

June 27, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SIGA, HRMY, ADPT, and SPRY Company Descriptions

Adaptive Biotechnologies NASDAQ:ADPT

$10.39 -0.11 (-1.05%)

Closing price 04:00 PM Eastern

Extended Trading

$10.62 +0.23 (+2.21%)

As of 04:34 PM Eastern

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Harmony Biosciences NASDAQ:HRMY

$35.20 -1.23 (-3.38%)

Closing price 04:00 PM Eastern

Extended Trading

$35.20 0.00 (0.00%)

As of 04:09 PM Eastern

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Siga Technologies NASDAQ:SIGA

$6.61 -0.09 (-1.34%)

Closing price 04:00 PM Eastern

Extended Trading

$6.61 0.00 (0.00%)

As of 04:20 PM Eastern

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

ARS Pharmaceuticals NASDAQ:SPRY

$17.92 -0.43 (-2.34%)

Closing price 04:00 PM Eastern

Extended Trading

$18.10 +0.18 (+1.03%)

As of 04:10 PM Eastern

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time